Evan J. McGillin

Evan regularly represents emerging growth companies throughout their entire life cycle, including formation, equity and debt financings, restructurings, M&A, and other strategic transactions. Additionally, Evan advises founders, senior management, and boards of directors on corporate governance, securities law compliance, equity and incentive structures, commercial agreements, and intellectual property matters.

Evan also represents angel, private equity, venture capital, strategic, and sovereign wealth fund investors in connection with financing transactions and M&A.

Financings

• Represented a gene therapy CDMO in multiple convertible debt and equity financings, raising more than $240 million in the aggregate
• Represented Slide, an artificial intelligence and insurtech startup, in its $100 million Series A financing
• Represented a content management and digital experience software company in its $80 million Series C financing
• Represented Particle Health Inc. in its $12 million Series A financing led by Menlo Ventures
• Represented a provider of a first-in-class epilepsy treatment in its $12 million convertible note financing
• Represented a medical device manufacturer in its recapitalization and $15 million Series B financing
• Represented the lead investors in a biopharmaceutical company’s $45 million Series C financing
• Represented a leading provider of loss-control software for property and casualty insurers in its Series A-1 financing
• Represented a US professional sports league in various equity and convertible debt financings
• Represented a high-performance computing startup in its spinout from a Fortune 100 technology company and subsequent debt and equity financings, raising more than $50 million

Strategic Mergers & Acquisitions

• Represented Engage Therapeutics Inc. in its sale to UCB (Euronext Brussels: UCB) for $125 million in upfront cash and up to $145 million in further potential milestone payments related to the clinical development, submission, and launch of Staccato® Alprazolam
• Represented Amneal Pharmaceuticals Inc. (NYSE: AMRX) in its acquisition of a 65.1% majority interest in federal healthcare company AvKARE and its related affiliate doing business as R&S Northeast, a transaction valued at $340 million
• Represented Humanwell Healthcare Group and PuraCap Pharmaceutical LLC in their acquisition of Epic Pharma of Laurelton, New York for $550 million
• Represented Quantum Global Technologies LLC in its sale to Ultra Clean Holdings, Inc. (NASDAQ: UCTT) for approximately $342 million
• Represented Marketeching Solutions, a leading research and social listening company, in its sale to W2O Group and its private equity sponsor Mountaingate Capital

Results may vary depending on your particular facts and legal circumstances.